J. Rex

D. Denning, F. Dromer, J. Rex, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

J. Cleary, W. Powderly, J. Rex, 2003, Antimicrobial Agents and Chemotherapy.

The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview.

R. Wenzel, J. Sobel, J. Wingard, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species

J. Perfect, M. Ghannoum, W. Schell, 2004, Journal of Clinical Microbiology.

Determination of Fungicidal Activities against Yeasts and Molds: Lessons Learned from Bactericidal Testing and the Need for Standardization

J. Rex, M. Pfaller, D. Sheehan, 2004, Clinical Microbiology Reviews.

In Vitro Synergy Testing of Anidulafungin with Itraconazole, Voriconazole, and Amphotericin B against Aspergillus spp. and Fusarium spp

J. Rex, V. Paetznick, L. Ostrosky-Zeichner, 2005, Antimicrobial Agents and Chemotherapy.

Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints

M. Ghannoum, J. Rex, T. Walsh, 2006, Journal of Clinical Microbiology.

Method for antifungal disk diffusion susceptibility testing of yeasts : Approved guideline

John H. Rex, Clinical, J. Rex, 2009 .

Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future HABP/VABP clinical trials.

R. Wunderink, J. Rello, M. Kollef, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks

H. Goossens, V. Fowler, A. McDonnell, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

J. Rex, A. Dane, B. Eisenstein, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.

B. Alexander, J. Wingard, H. Tamura, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Combating antimicrobial resistance: policy recommendations to save lives.

Brad Spellberg, Barry I Eisenstein, Edward Septimus, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

An insight into the antifungal pipeline: selected new molecules and beyond

Arturo Casadevall, John H. Rex, John N. Galgiani, 2010, Nature Reviews Drug Discovery.

Empirical Fluconazole versus Placebo for Intensive Care Unit Patients

G. Slotman, J. Sobel, P. Biswas, 2008, Annals of Internal Medicine.

A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

M. Levenstein, J. Rex, J. Bennett, 1994 .

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

J. Sobel, S. Filler, J. Rex, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Quality indicators assessing antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure

I. Okeke, N. Adriaenssens, M. Hulscher, 2018, The Journal of antimicrobial chemotherapy.

Prospective Survey of (1→3)-β-d-Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting

M. Finkelman, J. Rex, V. Paetznick, 2010, Journal of Clinical Microbiology.

Syscan3, a Kit for Detection of Anti-Candida Antibodies for Diagnosis of Invasive Candidiasis

J. Warmington, J. Rex, V. Paetznick, 2005, Journal of Clinical Microbiology.

Update on invasive candidiasis.

E. Anaissie, J. Rex, L. J. Rodriguez, 1997, Advances in pharmacology.

In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis

S. Seyedmousavi, J. Rex, K. Kwon-Chung, 2021, Antimicrobial agents and chemotherapy.

Microdilution Susceptibility Testing of Amphotericin B, Itraconazole, and Voriconazole against Clinical Isolates of Aspergillus and FusariumSpecies

J. Rex, S. Arikan, M. Lozano-Chiu, 1999, Journal of Clinical Microbiology.

Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections.

S. Chanock, E. Anaissie, A. Francesconi, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and Candida spp. as Determined by CLSI Broth Microdilution

M. Ghannoum, M. Castanheira, S. Lockhart, 2012, Journal of Clinical Microbiology.

Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods

M. Ghannoum, B. Alexander, J. Rex, 2009, Journal of Clinical Microbiology.

Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting

B. Alexander, J. Sobel, V. Morrison, 2007, European Journal of Clinical Microbiology & Infectious Diseases.

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

J. Rex, J. Bennett, J. Edwards, 1994, The New England journal of medicine.

In Vitro Activity of Nystatin Compared with Those of Liposomal Nystatin, Amphotericin B, and Fluconazole against Clinical Candida Isolates

J. Rex, S. Arikan, M. Lozano-Chiu, 2002, Journal of Clinical Microbiology.

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

E. Anaissie, J. Vazquez, D. Kontoyiannis, 2005, European Journal of Clinical Microbiology and Infectious Diseases.

Deeply invasive candidiasis.

B. Kullberg, J. Rex, J. Bennett, 2002, Infectious disease clinics of North America.

Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.

John H Rex, Kevin Outterson, J. Rex, 2016, The Lancet. Infectious diseases.

Patient Access in 14 High-Income Countries to New Antibacterials Approved by the US Food and Drug Administration, European Medicines Agency, Japanese Pharmaceuticals and Medical Devices Agency, or Health Canada, 2010–2020

J. Rex, K. Outterson, M. Zaman, 2021, Clinical Infectious Diseases.

Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.

J. Rex, K. Outterson, 2020, Translational research : the journal of laboratory and clinical medicine.

To the G20: incentivising antibacterial research and development.

L. Piddock, Francesco Ciabuschi, E. Baraldi, 2017, The Lancet. Infectious diseases.

Accelerating global innovation to address antibacterial resistance: introducing CARB-X

F. Franceschi, Peter Jackson, D. Hung, 2016, Nature Reviews Drug Discovery.

ND4BB: addressing the antimicrobial resistance crisis

J. Rex, 2014, Nature Reviews Microbiology.

Immunomodulation with interferon‐gamma and colony‐stimulating factors for refractory fungal infections in patients with leukemia

E. Anaissie, J. Rex, G. Dow, 2005, Cancer.

Intravascular Catheter Exchange and Duration of Candidemia

J. Serody, J. Rex, J. Bennett, 1995 .

Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

J. Sobel, J. Baddley, B. Kullberg, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice

E. Anaissie, G. Lopez-Berestein, J. Rex, 1997, Antimicrobial agents and chemotherapy.

Lipid-based antifungal agents: current status.

J. Rex, S. Arikan, 2001, Current pharmaceutical design.

Critical analysis of antibacterial agents in clinical development

K. Bush, S. Harbarth, J. Rex, 2020, Nature Reviews Microbiology.

Reference method for broth dilution antifungal susceptibility testing of filamentous fungi : Approved standard

Clinical, J. Rex, 2008 .

CHAPTER 89 – Mucormycosis

J. Rex, T. Walsh, M. Mcginnis, 2011 .

Antifungal drug resistance in pathogenic fungi.

F. Dromer, J. Rex, D. Sanglard, 1998, Medical mycology.

Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement

Steven D. Brown, Clinical, B. Alexander, 2008 .

Prospective Survey of (1 3 3)- (cid:1) - D -Glucan and Its Relationship to Invasive Candidiasis in the Surgical Intensive Care Unit Setting (cid:1)

M. Finkelman, J. Rex, V. Paetznick, 2010 .

Multidimensional flow-cytometric analysis of dendritic cells in peripheral blood of normal donors and cancer patients

D. Pierson, E. Anaissie, B. Melichar, 1997, Cancer Immunology, Immunotherapy.

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease

R. Kolamunnage-Dona, J. Rex, W. Hope, 2017, mBio.

Catastrophic Visual Loss Due to Cryptococcus neoformans Meningitis

G. Cloud, J. Rex, J. Bennett, 1993, Medicine.

New agents for the treatment of systemic fungal infections – current status

J. Rex, S. Arikan, 2002, Expert opinion on emerging drugs.

New agents for treatment of systemic fungal infections

J. Rex, S. Arikan, 2000 .

Activated lymphocytes reduce adherence of Aspergillus fumigatus.

E. Anaissie, D. Cohen, J. Rex, 1998, Medical mycology.

Aspergillus fumigatus conidia induce a Th1-type cytokine response.

E. Anaissie, J. Rex, C. Savary, 1997, The Journal of infectious diseases.

Characteristics of human dendritic cells generated in a microgravity analog culture system

D. Pierson, J. Rex, S. P. Tomasovic, 2001, In Vitro Cellular & Developmental Biology - Animal.

Resistance ofCandidaSpecies to Fluconazole

J. Rex, M. Rinaldi, A. Pfaller, 1995 .

European expert opinion on the management of invasive candidiasis in adults.

J. Vincent, J. Meis, T. Calandra, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Editorial Response: Estimating the True Cost of Amphotericin B

J. Rex, T. Walsh, 1999 .

Estimating the true cost of amphotericin B.

J. Rex, T. Walsh, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard

Clinical, J. Rex, M. Pfaller, 2008 .

The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed?

E. Anaissie, J. Rex, M. Grazziutti, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Addressing the need for new antibacterials--authors' reply.

C. Knirsch, J. Rex, W. Sanhai, 2013, The Lancet. Infectious diseases.

The value of single-pathogen antibacterial agents

B. Spellberg, J. Rex, 2013, Nature Reviews Drug Discovery.

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

M. Ghannoum, B. Alexander, Steven D. Brown, 2008, Journal of Clinical Microbiology.

Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses.

E. Anaissie, R. Sylvester, J. Sobel, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Amphotericin B: time for a new "gold standard".

J. Rex, K. Marr, Stuart H. Cohen, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups.

J. Powers, J. Galgiani, C. Viscoli, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Analysis of definitions used in clinical research on invasive fungal infections Consensus proposal for new, standardized definitions

D. Denning, J. Meis, J. Rex, 1999 .

Fungal infections in iatrogenically compromised hosts.

E. Anaissie, J. Rex, T. Walsh, 1998, Advances in internal medicine.

Candida in the peritoneum: passenger or pathogen?

J. Rex, 2006, Critical care medicine.

Ocular manifestations of candidemia.

J. Sobel, C. Viscoli, A. Rothova, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Voriconazole Salvage Treatment of Invasive Candidiasis

B. Kullberg, J. Rex, A. O. Oude Lashof, 2003, European Journal of Clinical Microbiology and Infectious Diseases.

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.

J. Serody, J. Rex, J. Bennett, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

When to change treatment of acute invasive aspergillosis: an expert viewpoint

Yee-Chun Chen, F. Marty, J. Rex, 2021, The Journal of antimicrobial chemotherapy.

FOCUS Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

M. Ghannoum, J. Rex, T. Walsh, 2001 .

Protection of human polymorphonuclear leukocyte function from the deleterious effects of isolation, irradiation, and storage by interferon‐γ and granulocyte‐colony‐stimulating factor

E. Anaissie, D. Cohen, J. Rex, 1995, Transfusion.

OP-JANM180122 59..66

I. Okeke, H. Goossens, N. Adriaenssens, 2018 .

Effects of Serum on In Vitro Susceptibility Testing of Echinocandins

J. Rex, V. Paetznick, L. Ostrosky-Zeichner, 2007, Antimicrobial Agents and Chemotherapy.

Therapeutic approach to Candida sepsis

J. Rex, P. Pappas, 1999, Current infectious disease reports.

Antifungal susceptibility testing: technical advances and potential clinical applications.

J. Rex, M. Pfaller, M. Rinaldi, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions.

J. Rex, M. Pfaller, A. Barry, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

J. Rex, M. Pfaller, P. W. Nelson, 1995, Antimicrobial agents and chemotherapy.

J. Rex, T. Walsh, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae.

H. Malech, J. Rex, J. Bennett, 1990, The Journal of infectious diseases.

Effect of the Echinocandin Caspofungin on Expression of Candida albicans Secretory Aspartyl Proteinases and Phospholipase In Vitro

J. Rex, L. Ostrosky-Zeichner, P. Belhumeur, 2002, Antimicrobial Agents and Chemotherapy.

Quality Control Limits for Broth Microdilution Susceptibility Tests of Ten Antifungal Agents

M. Ghannoum, Steven D. Brown, J. Rex, 2000, Journal of Clinical Microbiology.

Lack of correlation of 24‐ vs. 48‐h itraconazole minimum inhibitory concentrations with microbiological and survival outcomes in a guinea pig model of disseminated candidiasis

J. Rex, G. Leitz, V. Paetznick, 2010, Mycoses.

Comparison of PCR- and HinfI Restriction Endonuclease-Based Methods for Typing of Candida krusei Isolates

J. Rex, K. Marr, B. Sancak, 2004, Journal of Clinical Microbiology.

Isolates Candida krusei ofEndonuclease-Based Methods for Typing Comparison of PCR-and HinfI Restriction

J. Rex, K. Marr, B. Sancak, 2004 .

Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome

M. Ghannoum, J. Galgiani, J. Rex, 1996, Journal of clinical microbiology.

Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods

J. Rex, M. Pfaller, B. Buschelman, 1994, Journal of clinical microbiology.

Forum report: issues in the design of trials of drugs for the treatment of invasive aspergillosis.

J. Powers, J. Galgiani, C. Viscoli, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.

J. Powers, J. Galgiani, C. Viscoli, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Resistance of Candida species to fluconazole

J. Rex, M. Pfaller, M. Rinaldi, 1995, Antimicrobial agents and chemotherapy.

Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients.

J. Rex, M. Lozano-Chiu, M. Martins, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Correlation between in vitro and in vivo activity of antifungal agents against Candida species.

E. Anaissie, J. Rex, V. Paetznick, 1994, The Journal of infectious diseases.

Antifungal Susceptibility Testing of Isolates from a Randomized, Multicenter Trial of Fluconazole versus Amphotericin B as Treatment of Nonneutropenic Patients with Candidemia

J. Rex, P. W. Nelson, A. Barry, 1994 .

In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.

J. Rex, P. W. Nelson, M. Lozano-Chiu, 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

Necrotizing fasciitis due to group A streptococcus after an accidental needle-stick injury.

J. Rex, C. Hagberg, A. Rădulescu, 1997, The New England journal of medicine.

Efficacy of Olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous Disease

S. Seyedmousavi, J. Rex, K. Kwon-Chung, 2019, Antimicrobial Agents and Chemotherapy.

Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole

A. Bolmström, J. Rex, M. Pfaller, 1996, Journal of clinical microbiology.

In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi.

T. Sorrell, J. Rex, D. Law, 2018, Medical mycology.

Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models

M. Ghannoum, J. Rex, T. Walsh, 1998, Antimicrobial Agents and Chemotherapy.

Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi

J. Rex, J. Peter, T. Walsh, 1997, Journal of clinical microbiology.

Antifungal prophylaxis in the intensive care unit: who should get it?

J. Rex, 2006, Critical care medicine.

Reply to Dr. Chandrasekar (Clin Infect Dis 2001; 32:320-1) and Drs. Marr and Boeckh (Clin Infect Dis 2001; 32:321).

J. Sobel, S. Filler, J. Rex, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibiotic development — economic, regulatory and societal challenges

R. Laxminarayan, J. Rex, K. Outterson, 2019, Nature Reviews Microbiology.

39 – Drugs Active against Fungi, Pneumocystis, and Microsporidia

D. Stevens, J. Rex, 2015 .

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

J. Sobel, T. Calandra, D. Benjamin, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Guidelines for treatment of candidiasis.

J. Sobel, S. Filler, J. Rex, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

J. Sobel, S. Filler, J. Rex, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality.

G. Drusano, J. Rex, W. Hope, 2016, The Journal of antimicrobial chemotherapy.

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora

M. Ghannoum, J. Galgiani, J. Rex, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antifungal susceptibility testing

J. Galgiani, J. Rex, M. Pfaller, 1993, Clinical Microbiology Reviews.

Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

M. Ghannoum, J. Rex, T. Walsh, 2001, Clinical Microbiology Reviews.

Importance of Candida species other than Candida albicans as opportunistic pathogens.

E. Anaissie, R. Summerbell, J. Rex, 1998, Medical mycology.

Rationale for Reading Fluconazole MICs at 24 Hours Rather than 48 Hours When Testing Candida spp. by the CLSI M27-A2 Standard Method

M. Ghannoum, B. Alexander, Steven D. Brown, 2008, Antimicrobial Agents and Chemotherapy.

Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?

M. Sculpher, M. Jit, A. Sarker, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The evolution of the regulatory framework for antibacterial agents

John H Rex, Mark Goldberger, Barry I Eisenstein, 2014, Annals of the New York Academy of Sciences.

Alternatives to antibiotics-a pipeline portfolio review.

I. Henderson, R. Hancock, Christopher M Thomas, 2016, The Lancet. Infectious diseases.

Disk Diffusion Method for Determining Susceptibilities of Candida spp. to MK-0991

J. Rex, P. W. Nelson, M. Lozano-Chiu, 1999, Journal of Clinical Microbiology.

Invasive candidiasis in immunocompromised hospitalized patients.

John H Rex, J. Rex, L. Ostrosky-Zeichner, 2005, Archives of medical research.

Combination Antifungal Therapy

J. Perfect, Melissa D. Johnson, J. Rex, 2004, Antimicrobial Agents and Chemotherapy.

Cunninghamella bertholletiae infection associated with deferoxamine therapy.

J. Rex, L. Fries, K. Kwon-Chung, 1988, Reviews of infectious diseases.

Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine

J. Rex, M. Pfaller, B. Buschelman, 1995, Journal of clinical microbiology.

International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections.

M. Ghannoum, R. Rubin, J. Solomkin, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies.

John H Rex, Thomas J Walsh, E. Anaissie, 2003, Blood.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

D. Denning, J. Meis, D. Stevens, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Chapter 53 – Antifungal and Antiviral Therapy

J. Rex, L. Ostrosky-Zeichner, 2008 .

Treatment of Murine Fusariosis with SCH 56592

E. Anaissie, D. Loebenberg, J. Rex, 1999, Antimicrobial Agents and Chemotherapy.

Mycoses in AIDS.

J. Rex, O. Lortholary, B. Dupont, 2000, Medical mycology.

Glucan synthase inhibitors as antifungal agents.

J. Rex, M. Kurtz, 2001, Advances in protein chemistry.

Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography

D. Stevens, J. Rex, L. H. Hanson, 1991, Antimicrobial Agents and Chemotherapy.

Microdilution antifungal susceptibility testing of Candida albicans and Cryptococcus neoformans with and without agitation: an eight-center collaborative study

E. Anaissie, M. Larocco, J. Galgiani, 1996, Antimicrobial agents and chemotherapy.

Differential Antifungal Activity of Isomeric Forms of Nystatin

J. Rex, V. Paetznick, L. Ostrosky-Zeichner, 2001, Antimicrobial Agents and Chemotherapy.

Resistance to Antifungal Agents

J. Rex, B. Arthington-Skaggs, 2010 .

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

J. Sobel, J. Cleary, D. Cohen, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates

A. Bolmström, J. Rex, M. Pfaller, 1996, Journal of clinical microbiology.

Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study.

E. Anaissie, A. Francesconi, R. Summerbell, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fungal Drug Resistance Assays

J. Rex, S. Arikan, 2009 .

Administration of potassium iodide to normal volunteers does not increase killing of Sporothrix schenckii by their neutrophils or monocytes.

J. Rex, J. Bennett, John E. Bennett, 1990, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

Pharmacokinetics of Intravenous Itraconazole in Stable Hemodialysis Patients

J. Rex, G. Leitz, L. Ostrosky-Zeichner, 2004, Antimicrobial Agents and Chemotherapy.

In Vitro Activities of Investigational Triazoles against Fusarium Species: Effects of Inoculum Size and Incubation Time on Broth Microdilution Susceptibility Test Results

J. Rex, V. Paetznick, N. Paphitou, 2002, Antimicrobial Agents and Chemotherapy.

Species Trichosporon In Vitro Antifungal Susceptibilities of

J. Rex, V. Paetznick, N. Paphitou, 2014 .

Retinal Lesions as Clues to Disseminated Bacterial and Candidal Infections: Frequency, Natural History, and Etiology

John W. Miller, Charles A. Garcia, J. Rex, 2003, Medicine.

Nystatin LF (Aronex/Abbott).

J. Rex, S. Arikan, Sevtap Arikan, 2001, Current opinion in investigational drugs.

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

W. Powderly, J. Rex, J. Edwards, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.

E. Estey, H. Kantarjian, M. Finkelman, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Sporothrix schenckii fungemia without disseminated sporotrichosis

M. Burday, J. Rex, R. Kosinski, 1992, Journal of clinical microbiology.

β-D-glucan as a diagnostic adjunct for invasive fungal infections: Validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome

E. Estey, H. Kantarjian, M. Finkelman, 2004 .

b - d -Glucan as a Diagnostic Adjunct for Invasive Fungal Infections: Validation, Cutoff Development, and Performance in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome

M. Finkelman, J. Rex, R. Ridge, 2004 .

Successful management of Histoplasma capsulatum infection of an abdominal aortic aneurysm.

G. Sarosi, T. Wheeler, G. Lawrie, 1986, Journal of vascular surgery.

Multicenter comparison of a colorimetric microdilution broth method with the reference macrodilution method for in vitro susceptibility testing of yeast isolates.

J. Rex, M. Pfaller, B. Buschelman, 1994, Diagnostic microbiology and infectious disease.

Prophylactic antifungal therapy in the intensive care unit.

R. Weinstein, J. Sobel, J. Rex, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of a colorimetric method for detecting amphotericin B-resistant Candida isolates.

J. Rex, M. Lozano-Chiu, M. Lancaster, 1998, Diagnostic microbiology and infectious disease.

Successful treatment of extensive posttraumatic soft-tissue and renal infections due to Apophysomyces elegans.

C. Fife, J. Rex, P. Okhuysen, 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cleaning patient shower facilities: a novel approach to reducing patient exposure to aerosolized Aspergillus species and other opportunistic molds.

E. Anaissie, R. Summerbell, J. Rex, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Deep Candida infections in the neutropenic and non-neutropenic host: an ISHAM symposium.

J. Sobel, J. Rex, J. Bennett, 2000, Medical mycology.

Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia.

E. Anaissie, J. Rex, O. Uzun, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae.

H. Malech, J. Rex, J. Bennett, 1991, The Journal of infectious diseases.

Collaborative Study of Antibiotic Medium 3 and Flow Cytometry for Identification of Amphotericin B-Resistant Candida Isolates

J. Rex, R. Ramani, V. Chaturvedi, 2004, Journal of Clinical Microbiology.

Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients.

J. Rex, M. Lozano-Chiu, M. Martins, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Fluconazole Suspension for Oropharyngeal Candidiasis Unresponsive to Tablets

J. Rex, M. Martins, 1997, Annals of Internal Medicine.

The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis

J. Rex, G. Catano, T. Patterson, 2018, Antimicrobial Agents and Chemotherapy.

Disk Diffusion-Based Methods for Determining Candida parapsilosis Susceptibility to Anidulafungin

J. Rex, B. Goldstein, V. Paetznick, 2003, Antimicrobial Agents and Chemotherapy.

Predictors of adverse outcome in cancer patients with candidemia.

E. Anaissie, J. Rex, O. Uzun, 1998, The American journal of medicine.

Multilaboratory Testing of Antifungal Combinations against a Quality Control Isolate of Candida krusei

M. Ghannoum, J. Rex, T. Walsh, 2008, Antimicrobial Agents and Chemotherapy.

Galactomannan and the diagnosis of invasive aspergillosis.

J. Rex, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Systemic antifungal prophylaxis reduces invasive fungal infections in acute myelogenous leukemia

E. Estey, H. Kantarjian, E. Boutati, 2002 .

Analysis of the clinical antibacterial and antituberculosis pipeline.

John H Rex, Stephan Harbarth, Peter Beyer, 2019, The Lancet. Infectious diseases.

Safety and Tolerability of Voriconazole in Patients with Baseline Renal Insufficiency and Candidemia

J. Sobel, C. Viscoli, B. Kullberg, 2012, Antimicrobial Agents and Chemotherapy.

White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs

R. Ebright, J. Rex, H. Boucher, 2017, The Journal of infectious diseases.

Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

L. Czaplewski, C. Arias, S. Harbarth, 2022, Antimicrobial agents and chemotherapy.

Invasive candidiasis: turning risk into a practical prevention policy?

J. Sobel, J. Rex, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials.

J. Rex, N. Paphitou, L. Ostrosky-Zeichner, 2005, Medical mycology.

Editorial response: catheters and candidemia.

J. Rex, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effects of in vitro and in vivo cytokine treatment, leucapheresis and irradiation on the function of human neutrophils: implications for white blood cell transfusion therapy.

E. Anaissie, D. Cohen, J. Rex, 1997, Clinical and laboratory haematology.

A comprehensive regulatory framework to address the unmet need for new antibacterial treatments.

Wendy R. Sanhai, C. Knirsch, J. Rex, 2013, The Lancet. Infectious diseases.

The role of immunoreconstitution in the management of refractory opportunistic fungal infections.

E. Anaissie, J. Rex, E. Roilides, 1998, Medical mycology.

Designing development programs for non-traditional antibacterial agents

Kevin Outterson, Jonathan J. Darrow, John H. Rex, 2019, Nature Communications.

Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access

Y. Carmeli, M. Savic, I. Gyssens, 2018 .

The successful uptake and sustainability of rapid infectious disease and antimicrobial resistance point-of-care testing requires a complex ‘mix-and-match’ implementation package

A. van Belkum, A. Van den Bruel, S. Harbarth, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

Editorial overview: Use of PK-PD for antibacterial drug development: decreasing risk and paths forward for resistant pathogens.

J. Rex, S. Bhavnani, 2017, Current opinion in pharmacology (Print).

Metrics for quantifying antibiotic use in the hospital setting: results from a systematic review and international multidisciplinary consensus procedure

Arjun Srinivasan, John H Rex, Claudia Wild, 2018, The Journal of antimicrobial chemotherapy.

Antibiotic development — economic, regulatory and societal challenges

R. Laxminarayan, J. Rex, K. Outterson, 2019, Nature Reviews Microbiology.

Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.

J. Rex, A. Towse, J. Mestre-Ferrandiz, 2017, Health policy.

Critical analysis of antibacterial agents in clinical development

K. Bush, S. Harbarth, J. Rex, 2020, Nature Reviews Microbiology.

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

D. Kontoyiannis, J. Rex, L. Ostrosky-Zeichner, 2005, European Journal of Clinical Microbiology and Infectious Diseases.

Antibacterial R&D at a crossroads: We've pushed as hard as we can … now we need to start pulling!

J. Rex, K. Outterson, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Quality indicators for responsible antibiotic use in the inpatient setting: a systematic review followed by an international multidisciplinary consensus procedure

Arjun Srinivasan, John H Rex, Claudia Wild, 2018, The Journal of antimicrobial chemotherapy.

Cloning and characterization of a Candida albicans maltase gene involved in sucrose utilization

P. Williamson, J. Rex, J. Bennett, 1992, Journal of bacteriology.

Global Pull Incentives for Better Antibacterials: The UK Leads the Way

J. Rex, K. Outterson, 2023, Applied Health Economics and Health Policy.

Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020.

J. Rex, K. Outterson, M. Zaman, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Metrics to assess the quantity of antibiotic use in the outpatient setting: a systematic review followed by an international multidisciplinary consensus procedure

I. Okeke, H. Goossens, N. Adriaenssens, 2018, The Journal of antimicrobial chemotherapy.

Reply to Kaye and Belley, “Third-Generation Cephalosporin-Resistant Enterobacterales Are Critical Priority Pathogens, Too!”

L. Czaplewski, C. Arias, S. Harbarth, 2022, Antimicrobial agents and chemotherapy.

Evaluation of a Method for Identification of Candida dubliniensis Bloodstream Isolates

J. Rex, B. Sancak, V. Paetznick, 2003, Journal of Clinical Microbiology.

The Value of the Information That Can Be Generated: Optimizing Study Design to Enable the Study of Treatments Addressing an Unmet Need for Rare Pathogens

N. Stallard, J. Rex, A. Dane, 2022, Open forum infectious diseases.

Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients.

J. Rex, A. Wanger, J. Mohr, 2004, Diagnostic microbiology and infectious disease.

Pharmacokinetic-Pharmacodynamic Evaluation of Ertapenem for Patients with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

G. Dale, J. Rex, S. Bhavnani, 2019, Antimicrobial Agents and Chemotherapy.

The Challenge of Antimicrobial Resistance: New Regulatory Tools to Support Product Development

J. Rex, B. Eisenstein, B. Eisenstein, 2014, Clinical pharmacology and therapeutics.

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

Priya Sharma, B. Spellberg, J. Rex, 2012, Nature Reviews Drug Discovery.

Resistance to antifungal agents in the critical care setting: problems and perspectives.

J. Rex, M. Martins, 1996, New horizons.

Voriconazole in the Treatment of Invasive Aspergillosis: profile report

J. Rex, T. Patterson, 2013 .

Human ehrlichiosis causing left ventricular dilatation and dysfunction.

J. Rex, S. Kazi, N. N. Vanek, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

J. Sobel, S. Filler, J. Rex, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Alternatives to antibiotics-a pipeline portfolio review.

Martha R. J. Clokie, I. Henderson, R. Hancock, 2016, The Lancet. Infectious diseases.

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

W. Powderly, J. Rex, J. Edwards, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

European expert opinion on the management of invasive candidiasis in adults.

J. Vincent, J. Meis, T. Calandra, 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Analysis of the clinical antibacterial and antituberculosis pipeline.

L. Moja, L. Czaplewski, S. Harbarth, 2019, The Lancet. Infectious diseases.

Ocular manifestations of candidemia.

J. Sobel, C. Viscoli, A. Rothova, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antibiotic Development Incentives That Reflect Societal Value of Antibiotics.

T. File, V. Fowler, J. Rex, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.